financials have been released, page-71

One last note on revenues, 2010 'sale of goods' was almost 40% lower than 2009, thus earlier posts about the success of Elixia are just not credible.

Unless you have found a way to isolate the sales of Vital ET, as I did not, you simply can't draw any conclusions at all about the sales of Elixia. All you can say for sure is that virtually all the 2009 neutraceutical revenue of $670 K was derived from sales of Vital ET, and perhaps a portion of the 2010 neutraceutical revenue was derived from sales of Vital ET, or perhaps none of it was. The company simply does not say, and there is no real discussion of Vital ET anywhere in the report to indicate that it is a product still offered by the company.

I also note that there is no "cosmetic" or "skin care" category, and that the income in the "Pharmaceutical" category is entirely explained as income from Prophase. Accordingly, I am forced to conclude that any Elixia income is aggregated into the neutraceutical category where it loses its identity.

Perhaps a new category into which skin care products can be appropriately categorized would be appropriate in the future.